BCG vaccine

(redirected from Calmette-Guerin vaccine)
Also found in: Medical, Encyclopedia.
Related to Calmette-Guerin vaccine: bacillus Calmette-Guerin, bacille Calmette-Guérin vaccine

BCG vaccine

 (bē′sē-jē′)
n.
A preparation consisting of attenuated human tubercle bacilli that is used for immunization against tuberculosis.

[B(acillus) C(almette-)G(uérin) vaccine.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

BCG vaccine


n.
a vaccine made from weakened strains of tubercle bacilli, used to produce immunity against tuberculosis.
[1925–30; B(acillus)C(almette)-G(uérin)]
Random House Kernerman Webster's College Dictionary, © 2010 K Dictionaries Ltd. Copyright 2005, 1997, 1991 by Random House, Inc. All rights reserved.
References in periodicals archive ?
A child considered to be within the FIC category is one who received a dose of Bacillus Calmette-Guerin vaccine and Hepatitis B at birth; three doses of DPT/Pentavalent within the 6th, 10th and 14th weeks in the life of a child and one dose of the measles vaccine at nine months.
Saving lives by training innate immunity with bacille Calmette-Guerin vaccine. Proc Natl Acad Sci U S A 2012;109(43):17317-8.
In 1974, WHO established the Expanded Program on Immunization (EPI) to ensure that all children have access to four routinely recommended vaccines that protect against tuberculosis, diphtheria, tetanus, pertussis, polio, and measles (4): bacillus Calmette-Guerin vaccine (BCG), DTP, polio vaccine (Pol), and MCV WHO and UNICEF derive national coverage estimates through an annual country-by-country review of all available data, including administrative and survey-based coverage (5,6); in general, only doses administered through routine immunization visits are counted.* DTP3 coverage by age 12 months is a key indicator of immunization program performance.
The study involved the currently available bacille Calmette-Guerin vaccine and an experimental subunit vaccine candidate, H4:IC31, which uses the IC31 adjuvant available under license from Valneva.
The impact of a change in bacille Calmette-Guerin vaccine policy on tuberculosis incidence in children in Cape Town, South Africa.
The Bacillus Calmette-Guerin vaccine is given to infants in many parts of the world, but its efficacy against pulmonary TB is highly variable.
The Bacille Calmette-Guerin vaccine will not be available again in Ireland until later this year or early next year.
Prevention relies on screening programs and vaccination with the bacillus Calmette-Guerin vaccine. One-third of the world's population is thought to have been infected with M.
The immunological effect of revaccination with Bacille Calmette-Guerin vaccine at 19 months of age.